CD274 and urothelial carcinoma: In the anti-PD-L1 cohort (IMvigor210: urothelial carcinoma patients), patients with a low PyroScore exhibited significantly prolonged survival (Figure 11A), and the objective response rate was higher in the low-risk score group (Figure 11B).